ArticleMolecular cancer therapeutics2023

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.

Rhys D O Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.